This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakamura, M. Articles by Konishi, N. Search for Related Content PubMed PubMed Citation Articles by Nakamura, M. Articles by Konishi, N.

Novel Tumor Suppressor Loci on 6q22-23 in Primary Central Nervous System Lymphomas

Departments of Pathology [M. N., M. K., K. S., E. I., N. K.] and Neurosurgery [T. S., H. H., H. N.], Nara Medical University, 634-8521 Nara, Japan

Deletions on the long arm of chromosome 6 (6q) are one of the most common chromosomal alterations in systemic high-grade non-Hodgkin’s lymphomas. However, the locations of allelic deletions and their roles have not yet been reported in primary central nervous system lymphomas (PCNSLs), most of which are classed as non-Hodgkin’s lymphoma. We thus performed fine loss of heterozygosity (LOH) mapping of 6q in 29 samples of surgically resected PCNSLs using 39 microsatellite markers to identify commonly deleted regions. LOH was found at 1 or more loci at 6q22-23 in 19 samples (66%); furthermore, 18 of these samples shared a deletion in the same small (140 kb) region flanked by D6S1030 and D6S1690, a region in which the human R-PTP- gene (PTPRK) is reported to be located. Reverse transcription-PCR analysis of the mRNA from 4 cases with 6q deletions confirmed loss of this gene, and loss of PTPRK expression was observed in 76% (22 of 29) of tumors with immunohistochemistry. In addition, LOH on 6q22-q23 significantly correlated to shorter patient survival (12.8 ± 4.3 versus 23.4 ± 3.5 months; P < 0.0001). Our results suggest that a 140-kb deletion located at 6q22-23 may contain the putative tumor suppressor, PTPRK, that appears to be relevant to the pathogenesis and prognosis of PCNSLs.

This article has been cited by other articles:

				J. R. Flavell, K. R. N. Baumforth, V. H. J. Wood, G. L. Davies, W. Wei, G. M. Reynolds, S. Morgan, A. Boyce, G. L. Kelly, L. S. Young, et al. Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells Blood, January 1, 2008; 111(1): 292 - 301. [Abstract] [Full Text] [PDF]

				M. Nakamura, K. Shimada, E. Ishida, T. Higuchi, H. Nakase, T. Sakaki, and N. Konishi Molecular pathogenesis of pediatric astrocytic tumors Neuro-oncol, April 1, 2007; 9(2): 113 - 123. [Abstract] [Full Text] [PDF]

				J. Eswaran, J. E. Debreczeni, E. Longman, A. J. Barr, and S. Knapp The crystal structure of human receptor protein tyrosine phosphatase {kappa} phosphatase domain 1 Protein Sci., June 1, 2006; 15(6): 1500 - 1505. [Abstract] [Full Text] [PDF]

				S. E. Wang, F. Y. Wu, I. Shin, S. Qu, and C. L. Arteaga Transforming Growth Factor {beta} (TGF-{beta})-Smad Target Gene Protein Tyrosine Phosphatase Receptor Type Kappa Is Required for TGF-{beta} Function Mol. Cell. Biol., June 1, 2005; 25(11): 4703 - 4715. [Abstract] [Full Text] [PDF]

				J. N. ANDERSEN, P. G. JANSEN, S. M. ECHWALD, O. H. MORTENSEN, T. FUKADA, R. DEL VECCHIO, N. K. TONKS, and N. P. H. MOLLER A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage FASEB J, January 1, 2004; 18(1): 8 - 30. [Abstract] [Full Text] [PDF]